BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
VERA upcoming catalysts
Vera Therapeutics, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 1 FDA event(s). Subscribe to VERA (.ics).
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|
| No upcoming PDUFA date or AdCom found. |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| No trials in this window. |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-09-22 | P2 | Vera Therapeutics, Inc. VERA | NCT07020923 Monthly Dosing of Atacicept in IgAN | IgA Nephropathy (IgAN); Berger Disease | active not recruiting | 90 |
| 2026-03-15 est. | P3 | Vera Therapeutics, Inc. VERA | NCT05609812 Atacicept in Subjects With Active Lupus Nephritis (COMPASS) | Lupus Nephritis (LN) | withdrawn | |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.